Objective To explore the efficacy and safety of tenofovir (TDF)+ lamivudine (3TC)+ efavirenz (EFV)combina-tion therapy in the treatment of HBV/HIV coinfection and provide evidence for effective management of HBV/HIV coinfec-tion.Methods All the AIDS/HIV patients treated in our hospital from February 2011 to October 2011 were screened for eligi-bility in this analysis.Twenty eligible patients with HBV/HIV coinfection were treated with the TDF/3TC/EFV triplet regi-men.The efficacy and safety of the combination therapy were evaluated.Results Of the 15 patients who had completed study period of 48 weeks,all had conversion of HBV DNA to negative,2 had HBeAg seroconversion.The liver function tests were normal.HIV-RNA was below the limit of detection in 15 cases.CD4+ increased by 139.72±3.36/μL on average.The creati-nine and lactate levels were within normal limits.No adverse events were reported.Conclusions The TDF/3TC/EFV triplet regimen is safe and effective for treatment of HBV/HIV coinfection.It is appropriate to recommend this regimen as a standard therapy for HBV/HIV coinfection.%目的：探讨替诺福韦、拉米夫定、依非韦伦联合方案治疗乙型肝炎病毒/人类免疫缺陷病毒（HBV/HIV）合并感染的疗效和安全性，为临床治疗提供依据。方法对2011年2-10月首次来我院门诊就诊的 HIV/AIDS 患者进行普查，筛选20例符合条件的 HBV/HIV 合并感染者入组，予以替诺福韦、拉米夫定、依非韦伦联合抗病毒治疗，观察其疗效和安全性。结果完成48周观察期的15例患者 HBV DNA 全部阴转，2例出现 HBeAg 血清学转换，肝功能正常；15例 HIV-RNA 低于检测下限，CD4＋细胞计数平均增加（139．72±3．36）个/μL；肌酐、乳酸均正常，未发生不良事件。结论替诺福韦、拉米夫定、依非韦伦联合治疗 HBV/HIV 合并感染安全、有效，可作为 HBV/HIV 合并感染患者常规治疗方案。
展开▼
